ArticleMicrobes and infection2007
Inhibition of leukotriene biosynthesis abrogates the host control of Mycobacterium tuberculosis.
Article in Microbes and infection, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 84 citations in OpenAlex.
- Plasma LOX-Products and Monocyte Signaling Is Reduced by Adjunctive Cyclooxygenase-2 Inhibitor in a Phase I Clinical Trial of Tuberculosis Patients.Frontiers in cellular and infection microbiology · 2021Trial
- Ly6GeLife · 2026Article
- Effects of MK-886, an inhibitor of the 5-lipoxygenase-activating protein, on peripheral blood mononuclear cells from patients with Chagas' heart disease.Revista da Sociedade Brasileira de Medicina Tropical · 2026Article
- Article
- Toxoplasma gondii Infection Decreases Intestinal 5-Lipoxygenase Expression, while Exogenous LTBInfection and immunity · 2022Article
- Macrophage: A Cell With Many Faces and Functions in Tuberculosis.Frontiers in immunology · 2022Review
- Paradoxical Effect of LTBFrontiers in behavioral neuroscience · 2019Article
- Leukotriene BScientific reports · 2017Article
- Lipoxin A4, a 5-lipoxygenase pathway metabolite, modulates immune response during acute respiratory tularemia.Journal of leukocyte biology · 2017Article
- Macrophage-Bacteria Interactions-A Lipid-Centric Relationship.Frontiers in immunology · 2017Review
- Neutrophil derived LTB4 induces macrophage aggregation in response to encapsulated Streptococcus iniae infection.PloS one · 2017Article
- Matrikines are key regulators in modulating the amplitude of lung inflammation in acute pulmonary infection.Nature communications · 2015Article
- Duality of lipid mediators in host response against Mycobacterium tuberculosis: good cop, bad cop.F1000prime reports · 2015Review
- Article
- Mycobacterium tuberculosis expressing phospholipase C subverts PGE2 synthesis and induces necrosis in alveolar macrophages.BMC microbiology · 2014Article
- The leukotriene B₄/BLT₁ axis is a key determinant in susceptibility and resistance to histoplasmosis.PloS one · 2014Article
- Lipid mediators in immune dysfunction after severe inflammation.Trends in immunology · 2014Review
- The acute phase of Trypanosoma cruzi infection is attenuated in 5-lipoxygenase-deficient mice.Mediators of inflammation · 2014Article
- Protective role of 5-lipoxigenase during Leishmania infantum infection is associated with Th17 subset.BioMed research international · 2014Article
- Host-directed therapeutics for tuberculosis: can we harness the host?Microbiology and molecular biology reviews : MMBR · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
Abstract
Leukotrienes produced from arachidonic acid by the action of 5-lipoxygenase (5-LO) are classical mediators of inflammatory responses. Recently, it has been demonstrated that leukotrienes also play an important role in host defense against microorganisms. In vitro studies have shown that leukotrienes augmented the anti-mycobacterial activity of neutrophils. In this study, we examined the role of leukotrienes in regulating host response and cytokine generation in a murine model of tuberculosis. Administration of the 5-LO pathway inhibitor MK 886, which reduced lung levels of both the leukotriene B(4) and the anti-inflammatory substance lipoxin A(4) by approximately 50%, increased 60-day mortality from 14% to approximately 57% in Mycobacterium tuberculosis-infected mice, and increased lung bacterial burden by approximately 15-fold. Although MK 886-treated animals exhibited no reduction in pulmonary leukocyte accumulation, they did manifest reduced levels of nitric oxide generation and of the protective type 1 cytokines interleukin-12 and gamma interferon. Together our results demonstrate that 5-LO pathway product(s) - presumably leukotrienes - positively regulate protective Th1 responses against mycobacterial infection in vivo. Moreover, the immunosuppressive phenotype in infected mice observed with MK 886 is most consistent with inhibition of an activator (LTB(4)) rather than a suppressor (LXA(4)) of antimicrobial defense, suggesting the major effect of leukotrienes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.